Titan Pharmaceuticals, Inc.  

(Public, OTCMKTS:TTNP)   Watch this stock  
Find more results for OTC:TTNP
0.705
0.000 (0.00%)
Aug 28 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.44 - 0.99
Open     -
Vol / Avg. 0.00/157,129.00
Mkt cap 77.78M
P/E     -
Div/yield     -
EPS -0.06
Shares 110.33M
Beta 1.83
Inst. own 6%
Nov 11, 2015
Q3 2015 Titan Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Titan Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - 3:25PM EDT - Add to calendar
Aug 17, 2015
Q2 2015 Titan Pharmaceuticals Inc Earnings Call
Aug 13, 2015
Q2 2015 Titan Pharmaceuticals Inc Earnings Release
Jun 24, 2015
Titan Pharmaceuticals Inc at ROTH Healthcare Day - London
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -300.13% -65.91%
Operating margin -143.68% -95.31%
EBITD margin - -85.63%
Return on average assets -51.25% -12.24%
Return on average equity -296.23% -33.44%
Employees 13 -
CDP Score - -

Address

Suite 505, 400 Oyster Point Blvd
SAN FRANCISCO, CA 94080
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

Description

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan's drug candidate, Probuphine, is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson's disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 60
Sunil Ramraje Bhonsle President, Director
Age: 65
Joseph A. Akers Independent Director
Age: 69
Victor J. Bauer Ph.D. Independent Director
Age: 79
Eurelio M. Cavalier Independent Director
Age: 82
M. David David MacFarlane Ph.D. Independent Director
Age: 74
James R. McNab Jr. Independent Director
Age: 71